Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Shareholders of Lipetsk Energy Supply Company approved dividends for 3 months 2024

5/2/24 LPSB

KLVZ Kristall first time reported by IFRS

5/2/24 KLVZ

KVLZ Kristall reported for 2023 by RAS

5/2/24 KLVZ

OMZ reported for 3 months of 2024 by RAS

5/2/24 OMZZP

TNS Energy Rostov-on-Don reported for 2023 by IFRS

5/2/24 RTSB

VHZ reported for 3 months of 2024 by RAS

5/2/24 VLHZ

EL5-Energo reported for 3 months of 2024 by IFRS

5/2/24 ELFV

Fix Price network in Belarus reaches 300 outlets

5/2/24 FIXP

Rosseti North Caucasus reported for 3 months of 2024 by RAS

5/2/24 MRKK

Gazprom reported for 2023 by IFRS

5/2/24 GAZP